Vascular Tissue Matrix Market Report 2025

This Vascular Tissue Matrix market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The vascular tissue matrix market size has grown strongly in recent years. It will grow from $1.2 billion in 2024 to $1.3 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to the advancements in tissue engineering, the aging population, the rising number of surgical procedures, and the development of biocompatible materials.

The vascular tissue matrix market size is expected to see strong growth in the next few years. It will grow to $1.76 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to the increasing incidence of cardiovascular diseases (CVDs), advancements in regenerative medicine, rising awareness of organ and tissue donation, and government initiatives and funding. Major trends in the forecast period include collaborations and partnerships, the emergence of biodegradable and bioengineered matrices, rising awareness and early diagnosis, favorable government initiatives, and expansion of healthcare infrastructure.

The increasing adoption of minimally invasive procedures is expected to drive the growth of the vascular tissue matrix market. Minimally invasive procedures, which involve small or no incisions, are gaining popularity due to their advantages, such as faster recovery times, reduced risk of complications, and less post-operative pain compared to traditional surgeries. Vascular tissue matrices are essential in these procedures as they help support and regenerate blood vessels without requiring extensive surgery. For example, in January 2024, Intuitive Surgical Inc., a U.S.-based manufacturer of robotic systems, reported a 12% increase in the placement of their da Vinci surgical systems in the fourth quarter of 2023, highlighting the rising demand for minimally invasive approaches. As a result, the growth of minimally invasive procedures is boosting the vascular tissue matrix market.

Companies in the vascular tissue matrix market are focusing on developing innovative products, such as tissue matrices derived from human umbilical cord extracellular matrix (ECM), to gain a competitive edge. These tissue matrices, composed of structural proteins and molecules from the umbilical cord's ECM, serve as scaffolds for supporting cellular infiltration and tissue regeneration. For instance, in February 2024, StimLabs LLC, a U.S.-based biotechnology company, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Corplex P, a wound care device derived from human umbilical cord ECM. This novel product is designed to treat various types of wounds, including diabetic ulcers, pressure ulcers, surgical wounds, and trauma wounds.

In April 2023, Aziyo Biologics, a U.S.-based regenerative medicine company, partnered with LeMaitre Vascular Inc. to exclusively distribute its cardiovascular product line in the United States. This collaboration includes products made from an extracellular matrix derived from porcine small intestine submucosa, which are designed to enhance healing and reduce inflammation in surgical applications. LeMaitre Vascular Inc. is a U.S.-based medical device company that offers vascular tissue matrix products as part of its cardiovascular portfolio.

Major companies operating in the vascular tissue matrix market are Abbott Laboratories, Medtronic PLC, Stryker Corporation, Baxter International Inc., Boston Scientific Corporation, Terumo Corporation, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., Coloplast Group, Getinge Group, Integra LifeSciences Corporation, LivaNova PLC, C. R. Bard Inc., Artivion Inc., CryoLife Inc., LeMaitre Vascular Inc., Kensey Nash Corporation, Cardiva Medical Inc., Lombard Medical Technologies, Genzyme Corporation, Cook Medical Inc., Humacyte Inc., BioCardia Inc.

North America was the largest region in the vascular tissue matrix market in 2023. The regions covered in the vascular tissue matrix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vascular tissue matrix market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A vascular tissue matrix is a biomaterial scaffold designed to support the growth, repair, or regeneration of vascular tissues, which include arteries, veins, and capillaries. This matrix offers a three-dimensional structure that simulates the extracellular matrix (ECM) of natural vascular tissues, aiding in cell attachment, proliferation, and differentiation.

The main types of vascular tissue matrices are biologic and synthetic matrices. A biologic matrix is derived from natural tissues and cells, typically sourced from humans or animals. These matrices are used in medical procedures to replace or repair damaged tissues, facilitating natural healing by integrating with the body's own tissues. They find applications in various therapeutic fields such as orthopedics, dermatology, cardiology, neurology, oncology, and more, and are utilized in settings like hospitals and clinics.

The vascular tissue matrix market research report is one of a series of new reports that provides vascular tissue matrix market statistics, including vascular tissue matrix industry global market size, regional shares, competitors with a vascular tissue matrix market share, detailed vascular tissue matrix market segments, market trends and opportunities, and any further data you may need to thrive in the vascular tissue matrix industry. This vascular tissue matrix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vascular tissue matrix market consists of sales of wound care devices, stent grafts, vascular filters, and synthetic vascular grafts. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.